LKFT Lakefront Biotherapeutics - American Depositary Shares
关于 Lakefront Biotherapeutics - American Depositary Shares 公司概况（来自维基百科）
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
阅读更多
Lakefront Biotherapeutics (formerly known as Galapagos NV and Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
History
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.
In June 2022, the business announced it would acquire CellPoint for €125 million, with milestones of up to €100 million and AboundBio for $14million.
Effective April 1, 2022 Paul Stoffels replaced cofounder and CEO of 20 years Onno van de Stolpe.
In April 2026 the company was renamed to Lakefront Biotherapeutics.
Company
A German company, Galapagos Biopharma Germany GmbH, was established in 2019 and is headquartered in Munich, Germany. In December 2021, the company established an Austrian subsidiary, Galapagos Biopharma Austria GmbH, headquartered in Vienna, Austria.
Drugs
Filgotinib (GLPG0634) a selective inhibitor of JAK1 (Janus kinase 1) being developed for the treatment of rheumatoid arthritis and potentially Crohn's disease.
GLPG1205: a first-in-class GPR84-inhibitor currently under research for the treatment of inflammatory bowel disease.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
该股票代码尚无基本面数据。
激进投资者及 5%+ 股东 3 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P. ×4 申报 | 2025年7月28日 | 13.22% | 修订 | — | SEC |
| TANG CAPITAL MANAGEMENT, LLC, KEVIN TANG, TANG CAPITAL PARTNERS, LP, TANG CAPITAL PARTNERS INTERNATIONAL, LP, TANG CAPITAL PARTNERS III, INC, TANG CAPITAL PARTNERS IV, INC, CONCENTRA BIOSCIENCES, LLC | 2025年2月14日 | 7.50% | 初始申报 | 被动投资 | SEC |
| Van Herk Investments B.V., Van Herk Investments THI B.V., Van Herk Private Equity Investments B.V., Stichting Administratiekantoor Penulata, Van Herk Management Services B.V., Onroerend Goed Beheer – en Beleggingsmaatschappij A. van Herk B.V., A. van Herk Holding B.V., Stichting Administratiekantoor Abchrys, Adrianus van Herk | 2021年11月2日 | — | 初始申报 | 董事会活动 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 18 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| EWK · iShares, Inc. | 0.58% | 37133 SH | 2026年8月8日 | 每日 |
| QQQS · Invesco Exchange-Traded Fund Trus... | 0.47% | 3949 SH | 2026年8月8日 | 每日 |
| IBB · iShares Trust | 0.08% | 305498 SH | 2026年8月8日 | 每日 |
| PDN · Invesco Exchange-Traded Fund Trus... | 0.07% | 9655 SH | 2026年8月8日 | 每日 |
| IEUS · iShares Trust | 0.05% | 3396 SH | 2026年8月8日 | 每日 |
| VSS · VANGUARD INTERNATIONAL EQUITY IND... | 0.04% | 188173 SH | 2026年8月8日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.03% | 815 SH | 2026年8月8日 | 每日 |
| SCZ · iShares Trust | 0.02% | 113209 SH | 2026年8月8日 | 每日 |
| VGK · VANGUARD INTERNATIONAL EQUITY IND... | 0.01% | 119870 SH | 2026年8月8日 | 每日 |
| WSML · iShares Trust | 0.01% | 2543 SH | 2026年8月8日 | 每日 |
| IEUR · iShares Trust | 0.01% | 27247 SH | 2026年8月8日 | 每日 |
| IEFA · iShares Trust | 0.00% | 320356 SH | 2026年8月8日 | 每日 |
| IDEV · iShares Trust | 0.00% | 40908 SH | 2026年8月8日 | 每日 |
| IXUS · iShares Trust | 0.00% | 62087 SH | 2026年8月8日 | 每日 |
| VXUS · VANGUARD STAR FUNDS | 0.00% | 717158 SH | 2026年8月8日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.00% | 36160 SH | 2026年8月8日 | 每日 |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.00% | 483750 SH | 2026年8月8日 | 每日 |
| VSGX · VANGUARD WORLD FUND | 0.00% | 9595 SH | 2026年8月8日 | 每日 |